Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBKE38
|
|||
| Drug Name |
BBP-812
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Canavan disease [ICD-11: 5C50.E1] | Phase 1/2 | [1] | |
| Company |
Aspa Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aspartoacylase (ASPA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04998396) A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Adrenas Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.